How We Help

0
Donated to NET cancer research
0
Annual visitors to online resources
0
Annual patient email and phone inquiries
0
Patient & caregiver education sessions
HELP US HELP OTHERS

NET Cancer is the FASTEST growing class of CANCER worldwide

HELP US HELP OTHERS

Neuroendocrine Tumours (NETs) Overview

  • Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
  • NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
  • NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
  • NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
  • The cause of NETs is currently unknown.

Contact Us For Live Support

Support Lines:

416-628-3189

Toll Free: 1-844-628-6788

Latest CNETS Canada News

Campaign Shines Spotlight on Rare Cancer

November 9th, 2016|0 Comments

Media Release Campaign Shines Spotlight on Rare Cancer on November 10th –World NET Cancer Day Toronto, ON – November 10th, 2016 – Today is World NET Cancer Day. To raise awareness about NET cancer, coffee [...]

“LET’S TALK ABOUT NETs”

October 27th, 2016|0 Comments

Media Advisory “LET’S TALK ABOUT NETs” Campaign Shines Spotlight on Rare Cancer Toronto, ON – October 27, 2016 – Between 12,000 to 15,000 Canadians are estimated to have a rare type of cancer called NETs [...]

PRRT Clinical Trial Update – PMH Site

October 19th, 2016|0 Comments

On October 2, 2016, CNETS Canada held a Toronto Patient Education Day entitled PRRT Clinical Trial Update – PMH Site, with presentations by Dr. Rebecca Wong and Dr. Shereen Ezzat.  There were 30 attendees, an [...]

ESMO 2016 NET News

October 13th, 2016|0 Comments

Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced lung or thymus carcinoid receiving [...]

Donate to CNETS Canada